COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pilot Study of FFP104 Dose Escalation in PBC Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02193360
Recruitment Status : Unknown
Verified August 2016 by Fast Forward Pharmaceuticals.
Recruitment status was:  Recruiting
First Posted : July 17, 2014
Last Update Posted : August 24, 2016
Information provided by (Responsible Party):
Fast Forward Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the initial safety, tolerability and pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC

Condition or disease Intervention/treatment Phase
Primary Biliary Cirrhosis Drug: FFP104 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)
Study Start Date : May 2015
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : December 2017

Arm Intervention/treatment
Experimental: Single arm Dose Escalation Drug: FFP104
Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.

Primary Outcome Measures :
  1. Safety and tolerability of FFP104 in PBC subjects following repeat doses of FFP104 [ Time Frame: Days 1, 3, 5 and weeks 2 - 12, 14, 16 and 24 ]
    Safety outcomes include abbreviated physical examination, treatment emergent adverse events (TEAE), clinically significant changes in clinical haematology, clinical chemistry, and urinalysis.

Secondary Outcome Measures :
  1. Proportion of subjects with a 10% decrease in Alkaline Phosphatase (ALP) from baseline values [ Time Frame: Week 12 ]
  2. Proportion of subjects with a 25 and 40% decrease in ALP from baseline [ Time Frame: Weeks 4, 8 and 12 ]
  3. Proportion of subjects with ALP<1.67 from upper limit of normal (ULN), an ALP decrease >15% and bilirubin within normal levels [ Time Frame: Weeks 4, 8, 12 and 24 ]
  4. Proportion of subjects with a biochemical response according to 'Paris I' criteria: ALP≤ 3x ULN and Aspartate Transaminase (AST) ≤2x ULN and bilirubin ≤1mg/dL [ Time Frame: Weeks 4, 8, 12 and 24 ]
  5. To evaluate the individual and mean changes in serum liver biochemistry from baseline [ Time Frame: Weeks 2, 4, 8, 12, 16 and 24 ]
    Evaluation of individual and mean changes in lab values (serum ALP, AST, bilirubin, albumin and gamma glutamyl transpeptidase (GGT)) over time from baseline values

  6. To evaluate changes from baseline with Mayo Risk Score [ Time Frame: Weeks 4, 8, 12 and 24 ]
  7. To evaluate changes from baseline in the Patient Report Outcome PBC-40 Quality of Life [ Time Frame: Weeks 12 and 24 ]
  8. To evaluate changes from baseline in pruritus using the Visual Analog Scale (VAS) [ Time Frame: Weeks 12 and 24 ]
  9. To evaluate changes from baseline in fatigue using the VAS [ Time Frame: Weeks 12 and 24 ]
  10. To evaluate changes in serum FFP104 levels from baseline [ Time Frame: over time ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female Age between 18 and 75 years of age inclusive at the time of signing the informed consent
  • Established diagnosis of PBC according to the EASL criteria (European Association for the Study of the Liver 2009): A diagnosis of PBC can be made with confidence in adult patients with otherwise unexplained elevation of ALP and presence of anti-mitochondrial antibody (AMA≥1:40), and/or AMA type M2. A liver biopsy is not essential for the diagnosis of PBC in these patients, but allows activity and stage of the disease to be assessed.
  • Having a screening ALP serum level between 1.67 and 5x ULN inclusive.
  • Be on a stable dose of ursodeoxycholic acid (UDCA) 12-20 mg/kg/day for at least 3 months prior to Screening or intolerant of UDCA in the opinion of the investigator (no UDCA for at least 8 weeks prior to Screening).
  • Are not pregnant or breast feeding and do not plan to become pregnant or father a child during the study. Female subjects (of childbearing potential) must be willing to use two medically accepted forms of contraception throughout the study and must be willing to submit to pregnancy test(s). Male subjects must agree to use medically accepted contraception methods with their partners throughout the study as described above, unless they have had a prior vasectomy.
  • Has the ability to communicate adequately with the study staff and to comply with the requirements of the entire study, with the help of a caregiver, if applicable.

Exclusion Criteria:

  • Laboratory screening results

    • alanine transaminase (ALT) >5x ULN
    • aspartate transaminase (AST) >5x ULN
    • Total bilirubin >2x ULN. Isolated bilirubin >2x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%
    • Total white blood cells (WBC) <3000 cells/mm3
    • Absolute neutrophil count (ANC) <1500 cells/mm3
    • Platelet count <100,000/mm3
    • Prothrombin time (international normalized ratio (INR)> 1.2
  • Body mass index (BMI) ≥35 or suspected to have relevant nonalcoholic fatty liver disease (NAFLD) as based on the judgment of the Investigator at screening
  • Subject has a history of, or current viral hepatitis B or C (including hepatitis B surface antigen [HBsAg], hepatitis B core antibody and hepatitis C virus (HCV) antibody [anti-HCV] positivity), or a positive HIV antibody screen at time of screening
  • Recipients of liver or other organ transplantation or anticipated need for orthotropic organ transplantation in one year as determined by the Mayo Risk Score
  • Co-existing liver or biliary diseases, such as primary sclerosing cholangitis, choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), cholangiocarcinoma diagnosed or suspected liver cancers
  • Recurrent variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class B/C, Esophageal Varices, or refractory ascites within the previous 6 months of Screening (defined as date informed consent signed)
  • Have a family history (more than one first degree relative) of multiple thrombotic events or a personal history of any venous or arterial thrombotic event including deep vein thrombosis, stroke, myocardial infarction, pulmonary embolus, or peripheral arterial thromboembolic events
  • Prohibited medications 6 months prior to Screening: azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide and other systemic corticosteroids; potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin)
  • Prohibited medications 12 months prior to Screening: antibodies or immunotherapy directed against interleukins or other cytokines or chemokines
  • Subjects with recurrent bacterial infections (as judged by the Investigator) within 6 months prior to first dose of FFP104, active bacterial, fungal or mycobacterial infections observed during screening, or any recent episode of infection requiring hospitalizations or treatment with antibiotics (within the 3 months prior to first dose)
  • History of malignancy, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
  • Immunization with a live vaccine within 4 weeks of Screening with the exception of influenza vaccine and no planned immunisations within the period of the study
  • Known clinically significant cardiac disease (e.g., myocardial infarction or stroke, unstable angina, claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG) abnormality within the previous 12 months prior to Screening
  • Subjects with evidence of other serious, significant, acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study
  • History of recent (within 12 months of study) alcohol or drug abuse
  • Use of other immunosuppressive medications 4 weeks prior to Screening
  • Active tuberculosis (TB) in the past or currently suspected TB which is presently receiving treatment or prophylactic therapy, has a positive TB test (as defined by local biological requirements), or any significant abnormality on chest X-ray within 3 months prior to Screening
  • Subjects who have planned surgery during the study period or have undergone major surgery within the 3 months prior to Screening
  • Known clinically significant allergy or known hypersensitivity to drugs that, in the opinion of the Investigator, may affect the patient's safety
  • Known sensitivity to any component of the study drug or previous sensitivity reaction or other clinically significant reaction to intravenous medications or biologic therapy
  • Participated to another clinical trial within the past 30 days prior to Screening, or is still within a washout period of a previous clinical trial or has previously received FFP104 (PG102) or ch5D12 in this or any study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02193360

Layout table for location information
Amsterdam Medical Center Active, not recruiting
Amsterdam, Netherlands, 1100 DD
Erasmus University Medical Center Recruiting
Rotterdam, Netherlands
Contact: H R van Buuren, MD   
Principal Investigator: H R van Buuren, MD         
United Kingdom
University Hospital Birmingham Recruiting
Birmingham, United Kingdom
Contact: G Hirschfield, MD   
Royal Free Hospital Recruiting
London, United Kingdom
Contact: D Thorburn, MD   
Newcastle upon Tyne Hospitals Recruiting
Newcastle upon Tyne, United Kingdom
Contact: D Jones, MD    0191 213 7210      
Sponsors and Collaborators
Fast Forward Pharmaceuticals
Layout table for additonal information
Responsible Party: Fast Forward Pharmaceuticals Identifier: NCT02193360    
Other Study ID Numbers: FFP104-001
2014-001638-27 ( EudraCT Number )
First Posted: July 17, 2014    Key Record Dates
Last Update Posted: August 24, 2016
Last Verified: August 2016
Keywords provided by Fast Forward Pharmaceuticals:
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Liver Cirrhosis, Biliary
Pathologic Processes
Liver Diseases
Digestive System Diseases
Cholestasis, Intrahepatic
Bile Duct Diseases
Biliary Tract Diseases